

Gunderson Dettmer Represents The Column Group in Surrozen's \$175 Million Oversubscribed Private Placement

Client News

March 24, 2025

Gunderson Dettmer represented client [The Column Group](#) as an investor in [Surrozen's \\$175 million oversubscribed private placement](#). This new financing will help Surrozen (Nasdaq: SRZN), a biotechnology company pioneering Wnt pathway-based therapeutics, to advance its pipeline programs to provide new or improved treatment options for multiple severe and disabling eye diseases.

The Gunderson deal team was led by public companies partner Keith Scherer and senior associate John Maciejewski.

Companies

[The Column Group](#)

[Surrozen](#)

Related People



Keith J. Scherer
PARTNER
P +1 617 648 9231



John E. Maciejewski
ASSOCIATE
P +1 617 648 9242

Related Services

Fund Investments in Companies
Life Sciences
Private & Public Companies
Seed, Venture and Growth Financings

Featured Insights

FIRM NEWS

Gunderson Dettmer Commemorates 2025 Asian American and Pacific Islander Heritage (AAPI) Month

CLIENT NEWS

Brazilian Carbon Capture Company Mombak Announces \$30M Financing

CLIENT NEWS

Africa B2B OmniRetail Announces \$20M Financing

CLIENT NEWS

Glacier Announces Series A Financing to Expand Robot Recycling Fleet

CLIENT NEWS

Dataminr Announces \$100M Investment Led by Fortress Investment Group

CLIENT NEWS

Omnidian Announces \$87M Series C for Renewable Energy Performance

INSIGHTS

Splitting the Pie: How Savvy Founders Divide Ownership and Navigate Other Founder Equity Decisions

CLIENT NEWS

Chainguard Announces \$356 Million Series D Led by Kleiner Perkins and IVP

INSIGHTS

Client Insight: California AI Transparency Act

INSIGHTS

Client Insight: Prepare for BE-10 Benchmark Survey of US Direct Investment Abroad

INSIGHTS

Tech Brew Interviews Aaron Rubin in “Where the legal battle stands around copyright and AI training”

CLIENT NEWS

Latin America Fintech Belvo Announces \$15M Funding